ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2617

Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis

Vibeke Strand1, Namita Tundia2, Yan Song3, Dendy Macaulay4 and Mahesh Fuldeore5, 1School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2AbbVie, Inc., North Chicago, IL, 3Analysis Group, Inc., Boston, MA, 4Analysis Group, Inc., New York, NY, 5AbbVie, Inc, North Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, Biologic drugs, economics and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This study assessed the direct and indirect economic burden among RA patients who had inadequate responses to initial biologic therapy compared with treatment responders.

Methods: Data from 1/1/1998-3/31/2014 were used from a large de-identified, privately insured claims database, which included work loss from a subset of reporting companies. Study sample consisted of patients with ≥1 claim for a biologic DMARD (bDMARD) approved for treatment of RA and ≥2 RA diagnoses in the claim history, with continuous eligibility for 6 months before (baseline) and 12 months after (study period) the date of the first bDMARD claim (index date). Patients were classified as responders and non-responders based on a validated, claim-based algorithm. All-cause and RA-related healthcare resource use and costs, work loss, and indirect costs during the study period were compared for bDMARD responders vs. non-responders. Multivariable regressions were used to adjust for baseline characteristics. As different treatments were approved over time and the pattern of costs and resources use may have changed, subgroup analyses of resource use and direct costs were conducted for patients with index dates in 1998-2007 and in 2008-2013.

Results: This study included 7,540 eligible RA patients, with 2,527 bDMARD responders and 5,013 non-responders; 407 responders and 723 non-responders had work loss data. Compared with responders, non-responders had significantly higher adjusted rates of resource use, including inpatient admissions (incidence rate ratio [IRR]=1.94), outpatient visits (IRR=1.19), emergency department visits (IRR=1.53), and number of prescription fills (IRR=1.09) (all p-values < 0.001). Non-responders had significantly higher adjusted all-cause and RA-related medical costs compared with responders (all-cause: $12,868 vs. $9,621, RA-related: $5,740 vs. $4,495, adjusted p-values<0.001) (Figure 1). Results for subgroup analyses of resource use and direct costs by index date were consistent with the full sample. Non-responders also had significantly more days of work loss compared with responders (22.1 vs. 16.7 days, IRR=1.21, adjusted p-value=0.007) and higher indirect costs ($3,548 vs. $2,890, adjusted p-value = 0.002).

Conclusion: Two-thirds of RA patients had inadequate responses to their initial bDMARD. These non-responders faced a significantly higher burden, including increased healthcare resource use, direct medical costs, and work loss compared to responders. Figure 1. Medical costs of biologic non-responders vs. responders


Disclosure: V. Strand, AbbVie, 5; N. Tundia, AbbVie, 1,AbbVie, 3; Y. Song, Analysis Group, Inc, 3; D. Macaulay, Analysis Group, Inc, 3; M. Fuldeore, AbbVie, 1,AbbVie, 3.

To cite this abstract in AMA style:

Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M. Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/economic-burden-of-non-responders-to-biologic-dmard-treatments-in-rheumatoid-arthritis/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/economic-burden-of-non-responders-to-biologic-dmard-treatments-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences